Full Press Release Details
Simon, M.D. Cellectis' EVP & Chief Operating Officer, to Serve as
Interim Chief Medical Officer
NEW YORK--(BUSINESS WIRE)--October 4, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a clinical-stage biopharmaceutical company focused on developing
immunotherapies based on gene-edited allogeneic CAR T-cells (UCART),
announced today that Mathieu Simon M.D. will act as Interim Chief
Medical Officer, effective immediately. Dr. Simon is taking over the
responsibilities of Loan Hoang-Sayag, Chief Medical Officer, who is
leaving Cellectis to pursue other opportunities.
Dr. Mathieu Simon has served as Cellectis' Executive Vice-President
since 2012 and as Chief Operating Officer since 2013. Dr. Simon was
Chief Executive Officer of former subsidiary Cellectis therapeutics and
has been instrumental in the strategic and operational management of all
therapeutic activities.
Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing - built on its flagship TALEN technology and
pioneering electroporation system PulseAgile - Cellectis uses the power
of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
owned by the Cellectis Group.
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risks factors that may affect company
business and financial performance, is included in filings Cellectis
makes with the Security Exchange Commission from time to time and its
financial reports. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
VP of Communications
Kasunich, 212-896-1241
KCSA Strategic Communications
Harnest, 646-385-9008
VP of Corporate Strategy and Finance